• 1
    DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 14, 2011. Available at (accessed 15 October 2012).
  • 2
    European AIDS Clinical Society. Clinical management and treatment of HIV-infected adults in Europe. Version 6.0 – October 2011. Available at (accessed 15 October 2012).
  • 3
    Clotet B, Bellos N, Molina J-M et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 11691178.
  • 4
    Madruga JV, Berger D, McMurchie M et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 4958.
  • 5
    Cahn P, Fourie J, Grinsztejn B et al. Week 48 analysis of once-daily vs twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25: 929939.
  • 6
    Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS 2008; 22: 13891397.
  • 7
    Mills A, Nelson M, Jayaweera D et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 16791688.
  • 8
    Lathouwers E, DeMeyer S, Dierynck I et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther 2011; 16: 99108.
  • 9
    Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156163.
  • 10
    Hughes RA, Sterne JA, Walsh J et al. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med 2011; 12: 583593.
  • 11
    Uy J, Yang R, Thiry A et al. Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated with atazanavir/r and lopinavir/r in the CASTLE study. J Int AIDS Soc 2008; 11 (Suppl. 1): P8.
  • 12
    Pulido F, Estrada V, Baril JG et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials 2009; 10: 7687.
  • 13
    Molina JM, Andrade-Villanueva J, Echevarria J et al. Once daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646655.
  • 14
    Zhu T, Chiu Y, Doan T et al. New tablet formulation of lopinavir/ritonavir is bioequivalent to the capsule at a dose of 800/200 mg. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, USA, December 2005 [Poster H-1894].
  • 15
    Tomaka F, Lefebvre E, Sekar V et al. Effects of ritonavir-boosted darunavir versus ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 2009; 10: 318327.
  • 16
    Overton T, Aberg JA, Gupta S et al. METABOLIK: Week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir. 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2010 [Abstract P74].
  • 17
    Moal G, Beraud G, Prazuck T, Hocqueloux L, Dupuis A, Venisse N. Lopinavir to atazanavir or darunavir switch in HIV-1 infected patients with dyslipidemia: an observational study. J Int AIDS Soc 2010; 13 (Suppl. 4): P46.
  • 18
    Skiest D, Cohen C, Khanlou H et al. Randomized comparison of DRV/r vs ATV/r on serum lipids in HIV+ persons on fully suppressive LPV/r or FPV/r with high serum triglycerides. 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA, February–March 2011 [Abstract 817].